Interferon alpha-2b (HanAll Biopharma)

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameInterferon alpha-2b (HanAll Biopharma)
Drug Alias NameResis-IFN-alpha-2bHanferonHL-031 (oral interferon alpha-2b)-HanAll BiopharmaHL-143 (subcutaneous interferon alpha-2b)-HanAll Biopharma
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunostimulantsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsHepatitis C, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNautilus Biotech
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHanAll Biopharma Co Ltd
Active IndicationsN/A
Inactive IndicationsHepatitis C, Chronic

Other Information

ATC CodeN/A
Related LinksWikipedia